TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1

Historical Portfolio Holders from Q3 2018 to Q2 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Debt / NOTE 2.500% 9/1
Principal, excl. options Q2 2024
67.3M
Holdings value Q2 2024
$58.8M
Value change Q2 2024
$0
Grand Portfolio weight change Q2 2024
0%
Number of holders
6
Number of buys Q2 2024
0
Number of sells Q2 2024
0
Average buys Q2 2024 %
0
Average sells Q2 2024 %
0
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Principal Value Change Price Investors
2024 Q2 $67.3M $58.8M $0 $0.87 6
2024 Q1 $67.3M $59.9M +$123K $0.88 7
2023 Q4 $67.8M $57.6M $0 $0.85 7
2023 Q3 $67.8M $58.2M $0 $0.85 7
2023 Q2 $67.8M $60.9M -$11.4K $0.89 7
2023 Q1 $67.7M $65.1M +$234K $0.95 6
2022 Q4 $67.7M $62.5M -$13.2M $0.92 8
2022 Q3 $30M $30.2M -$3.98M $1.01 10
2022 Q2 $34M $33.6M -$34.6M $0.99 11
2022 Q1 $67.6M $70.2M -$194M $1.04 22
2021 Q4 $246M $270M +$10.4M $1.09 33
2021 Q3 $238M $239M +$41.2M $1.01 32
2021 Q2 $202M $172M -$1.72M $0.85 32
2021 Q1 $201M $205M -$29.2M $1.02 30
2020 Q4 $229M $233M +$4.19M $1.01 29
2020 Q3 $231M $197M +$10.8M $0.85 33
2020 Q2 $209M $173M -$9.51M $0.82 34
2020 Q1 $269M $207M +$36.4M $0.78 37
2019 Q4 $222M $174M +$399K $0.78 31
2019 Q3 $221M $166M +$82.2K $0.74 30
2019 Q2 $219M $198M +$2.53M $0.90 35
2019 Q1 $216M $203M +$3.3M $0.93 32
2018 Q4 $212M $190M -$21.1M $0.90 31
2018 Q3 $223M $229M +$229M $1.03 29